Form 4: Terns Pharmaceuticals Director Ann Elizabeth Taylor Receives Stock Option in Lieu of Cash Retainer

Director Ann Elizabeth Taylor of Terns Pharmaceuticals received a stock option for 4,676 shares in lieu of a $20,000 cash retainer for the third and fourth quarters of 2024.

Summary

• Ann Elizabeth Taylor, a director at Terns Pharmaceuticals, received a stock option on July 1, 2024, for 4,676 shares of common stock.
• The option was granted in lieu of a $20,000 cash retainer fee for the third and fourth quarters of 2024, as per the Issuer's Non-Employee Director Compensation Policy.
• The exercise price of the stock option is $6.85.
• The option vests in monthly installments, with full vesting occurring on January 1, 2025.
• The option expires on June 30, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, suggesting stability and alignment of interests. The director accepting stock in lieu of cash is a mildly positive signal.

Positives

• The director's decision to receive stock options instead of cash may signal confidence in the company's future performance.
• The vesting schedule aligns the director's interests with the long-term success of the company.

Future Outlook

The document does not contain specific forward-looking statements, but the grant of stock options suggests an expectation of future value creation.

Industry Context

Stock options are a common form of compensation for directors, aligning their interests with shareholders and incentivizing long-term value creation. This is a standard practice in the pharmaceutical industry.

Comparison to Industry Standards

• Director compensation packages often include a mix of cash retainers and equity-based awards.
• The size and vesting schedule of the stock option are typical for non-employee directors in similar-sized pharmaceutical companies.
• Comparing Terns Pharmaceuticals' director compensation structure to companies like Madrigal Pharmaceuticals or Viking Therapeutics would provide further context.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning the director's interests with the company's long-term success.
• Employees may see this as a sign of confidence in the company's future.

Key Dates